Liu et al. (2019) Reported that ginsenoside Rg3 could upregulate VRK1 expression and P53BP1 foci formation in response to DNA damage, thereby inhibiting the tumorigenesis and viability of cancer cells. Futhermore, ginsenoside Rg3 could enhance the anticancer activity of Gefitinib through increasing apoptosis and decreasing migration in NSCLC cell lines (Dai et al., 2019). Here, VRK1 is linked to cancer.